THE ADVISORY BOARD
The Advisory Board held its inaugural meeting in July 2016 to oversee the formation of the Alliance. Chaired by former Victorian Premier, the Honourable John Brumby, the Board is made up of executive level representation from many of the most influential actors in global health operating out of Melbourne, and highlights the diversity of the sector, representing players from research, education, biotechnology, service delivery and advocacy.
Board members are drawn from AFAO, Burnet Institute, CSIRO, The Fred Hollows Foundation, Global and Women’s Health Unit at Monash University, Medicines Development for Global Health, Monash Sustainable Development Institute, The Nossal Institute for Global Health, and the University of Melbourne.
Honourable John Brumby
The Hon John Brumby was the former Premier of Victoria (2007 – 2010) and has immense experience in public life serving for more than 10 years as Treasurer and then Premier of Victoria, 6 years as Leader of the Victorian Opposition and 7 years as Federal MHR for Bendigo during the period of the Hawke Government. Since retiring from politics, Mr Brumby has accepted a number of appointments in both the business and not-for-profit sectors, including: Professorial Fellow at both the University of Melbourne and Monash University; Chairman of the Motor Trades Association of Australia (MTAA) Superannuation Fund; Chair of the Olivia Newton-John Cancer Research Institute; Chair of the Fred Hollows Foundation; Chair of National Centre for Workplace Leadership; and National President of the Australia China Business Council.
Professor Jane den Hollander AO
Chair, Global Health Alliance Australia
Professor Jane den Hollander AO was Vice-Chancellor of Deakin University Australia from July 2010 until her retirement in July 2019. At Deakin, Professor den Hollander introduced LIVE the future, an aspiration for Deakin to drive the digital frontier in higher education, harnessing the power, opportunity and reach of new and emerging technologies in all that it does.
Professor den Hollander interests particularly include i) equity and inclusion with a focus to ensure good education and health for all Australians and in particular Indigenous peoples and women; ii) innovation related to the start up sector and the continuing role of digital technology and AI in our collective future. Professor den Hollander is a Director of UniSuper Limited and Trustee and chair of its Remuneration Committee. Prior to taking up her appointment as Vice-Chancellor of Deakin University, Professor den Hollander was Deputy Vice-Chancellor (Academic) at Curtin University in Western Australia.
Professor den Hollander received an Order of Australia for her distinguished service to tertiary education in the 2017 Australia Day Honours awards.
Ms. Misha Coleman
Executive Director, Global Health Alliance Australia
Since 2017 Misha has led the Alliance, which is a peak body for global health organisations in Australia and which currently has 47 organisational members across nine organisational types. Misha has had a number of leadership roles in global health in both government and the not-for-profit sector, with post-graduate qualifications in international development, women’s health, community development, monitoring and evaluation, project design and management, governance and compliance. In 2018 she authored Victoria’s first International Health Sector Capacity Report, and the Alliance has recently been funded to provide a Secretariat for Australia and New Zealand’s 52 WHO Collaborating Centres.
Misha has extensive experience living and working in countries including Bougainville, Palestine, Ethiopia, Kenya, Vietnam and Cambodia. She was formerly the CEO of Anglican Overseas Aid, and has also worked in several roles at AusAID, as the Country Manager of the Australian Centre for International Agricultural Research at the Australian Embassy in Hanoi, and she has led Asian Development Bank and US Government aid programs in the Asia-pacific region. She was formerly a midwife and worked in South African townships during apartheid and in several Australian indigenous communities.
Professor Brendan Crabb AC
Director, Burnet Institute
Professor Brendan Crabb AC is the Director and CEO of Burnet Institute and the current Chair of the Victorian Chapter of the Association of Australian Medical Research Institutes. He was President of the Association of Australian Medical Research Institutes from 2012 -2014. Professor Crabb was awarded a Companion of the Order of Australia (AC) for his contributions to medical research and global health in the 2015 Australia Day honours.
He is a medical researcher and health administrator and advocate committed to improving the lives of poor, vulnerable and marginalised communities. Professor Crabb is a molecular biologist with a particular interest in infectious diseases and in health issues of the developing world. appointments at The University of Melbourne and Monash University. Until his appointment as Director of Burnet Institute he was a Senior Principal Research Fellow of the National Health & Medical Research Council of Australia, and an International Research Fellow of the US-based Howard Hughes Medical Institute.
Dr. Krystal Evans
Former Chief Executive Officer at BioMelbourne Network
Dr Krystal Evans was the former Chief Executive Officer of the BioMelbourne Network and has over 15 years’ experience in the biomedical research sector. Krystal’s skills in government affairs, stakeholder relations and business development underpin her commitment to advancing Victoria’s unique position as a global destination for life sciences and health technology. Krystal is a leading advocate for science and technology, and was a founding member and Chair of the Australian Academy of Science’s Early and Mid-Career Researcher Forum.
A champion of the 2011 “Discoveries Need Dollars” campaign, she led the Melbourne “Rally for Research” to protect funding for medical research in Australia. Krystal is an articulate and popular spokesperson, and is a regular presenter on Melbourne community radio station 3RRRFM’s science show “Einstein A-Go-Go”. Krystal has an undergraduate degree in medicinal chemistry and holds a PhD in medical biology, undertaken at the Walter and Eliza Hall Institute. Formerly, Krystal led a malaria vaccine development program at the Walter and Eliza Hall Institute, which attracted funding from the Bill and Melinda Gates Foundation, the NHMRC and Commercialisation Australia. In this role she was responsible for positioning lead malaria vaccine candidates for progression into early-phase clinical trials.
Ms. Helen Evans AO
Melbourne Global Health and Development Alliance (MGHDA) Exploratory Phase Project Lead
Executive Committee Member
Helen Evans AO served as Deputy CEO at Gavi, The Vaccine Alliance based in Geneva from 2009 until her retirement in 2014. Prior to joining Gavi, she served as Deputy Executive Director at the Global Fund to Fight AIDS, Tuberculosis and Malaria, also based in Geneva, between 2005 and 2009. Now living in Melbourne Helen has an honorary appointment as Associate Professor at The Nossal Institute for Global Health at the University of Melbourne, and serves as member of the Board of The Fred Hollows Foundation and of the Burnet Institute. She is also a member of the Technical Evaluation Reference Group of The Global Fund to Fight AIDS, Tuberculosis and Malaria, a member of the Technical Reference Group for the Australian Government’s Regional Health Security Initiative, a member of the Foundation Committee of the Global Health Alliance Australia, and a fellow of the Australian Institute of International Affairs.
Ms Jennifer Gersbeck
Director, Global Partnerships & Advocacy at The Fred Hollows Foundation
Executive Committee Member
Jennifer was recently appointed the Director of Global Partnerships and Advocacy at Fred Hollows Foundation. Previously CEO for Vision 2020 Australia and a member of the executive team of World Vision Australia and Department of Health, Jennifer is now internationally recognised as a not-for-profit/public sector strategist, leader and sought after speaker. Jennifer utilises her expertise in change management and communications to cultivate organisational cultures that involve and foster consensus and commitment towards common goals. This coupled with Jennifer’s strong track record of strategic resource mobilisation and integration of effective advocacy and public relations activities leading to greater funding opportunities and cost minimisation is further demonstration of her abilities.
Professor Jane Fisher
Finkel Professor of Global Health and Director at Global and Women’s Health Unit, Monash University
Jane Fisher, Director of the Global and Women’s Health Unit, is an academic Clinical and Health Psychologist with longstanding interests in the social determinants of health. Her research focuses on gender-based risks to women’s mental health and psychological functioning from adolescence to mid-life, in particular related to fertility, conception, pregnancy, the perinatal period and chronic non-communicable diseases; and on parenting capabilities and early childhood development in low- and high-income settings. She has completed major epidemiological studies in clinical and community settings in Australia and Vietnam, nationally funded intervention trials, and has supervised more than 30 research higher degree and postgraduate coursework projects to completion. She is an expert technical advisor to international agencies including the World Health Organization, UNICEF and the United Nations Population Fund.
Professor Barbara McPake
Director, Nossal Institute for Global Health
Professor Barbara McPake is the Director of the Nossal Institute for Global Health. She is a health economist and international leader in the study of health systems and financing in emerging economies. Barbara was at the London School of Hygiene and Tropical Medicine and the Queen Margaret University in Edinburgh. Her research includes studies in Africa, South and Southeast Asia and her extensive work has been published in leading international journals.
Managing Director, Medicines Development for Global Health
Mark has over 20 years’ experience in the development of small molecules, therapeutic and prophylactic vaccines and microbicides. This experience includes 10 years with Glaxo (now GSK) at their research and development headquarters in London, United Kingdom, two years with Gilead Sciences at their head office in San Francisco, USA and three years at University of New South Wales. Mark has a clinical research background which encompasses first-in-human, proof-of-concept, pivotal phase II and III, phase IIIb and phase IV studies and regulatory submissions (two New Drug Applications).